• Key competencies
    • Multi-disciplinary mindset to design an integrated approach to market access challenges.
    • Aptitude to interact and communicate effectively in a cross-cultural and cross-functional environment.
    • Strategic thinking to achieve a competitive advantage in today’s Value-based and Health Technology Assessment driven environment.
  • Abbreviated CV
    • Mar 2014 - current
    • Director, Xintera Ltd (Cambridge, UK)
    • Oct 2010 - Feb 2014
    • Managing Director, Xintera Consulting bvba (Leuven, Belgium)
    • Nov 2008 - Sep 2010
    • Associate Director, European Health Economics & Outcomes Research, Virology Lead, BMS International (Braine l’Alleud, Belgium)
    • Feb 2007 - Oct 2008
    • Associate Director, Health Economics & Outcomes Research EU Markets (BENELUX, Switzerland, Greece, Turkey), BMS International (Braine l’Alleud, Belgium)
    • Nov 2005 - Jan 2007
    • Acting Associate Director, Outcomes Research, Pfizer Canada Inc. (Montreal, Canada)
    • 2002 - 2005
    • Senior Manager, Outcomes Research, Pfizer Canada Inc. (Montreal, Canada)
    • 1999 - 2002
    • Outcomes Research Manager, Pfizer Canada Inc. (Montreal, Canada)
    • 1998 - 1999
    • Outcomes Research Consultant to Pfizer Inc., (New York, USA)
    • 1990 - 1991
    • Public health nurse (‘sociaal verpleegkundige’), Prince Leopold Institute of Tropical Medicine (Antwerp, Belgium
    • 1988 - 1990
    • Tropical Nurse, Médecins sans Frontières (Sudan, Mali)
    • 1987 - 1988
    • Nurse practitioner in different health care settings, Flanders, Belgium
  • Publications
    • Ophthalmology
      • The MeMo Study: an observational study estimating the prevalence of metamorphopsia in patients with vitreomacular traction, with or without macular hole (MH) and its impact on health related quality of life. Presented at the British and Eire Association of Vitreoretinal Surgeons, UK. November 2015

      • Improved visual function is associated with inflammation reduction in subjects with non-infectious uveitis (NIU) of the posterior segment treated with intravitreal sirolimus: Results from SAKURA study 1. Lescrauwaet B. Duchateau L. Verstraeten T. Thurau S. Value in Health (2015) 18:7 (A426). Date of Publication: November 2015

      • Cost effectiveness of ocriplasmin for the treatment of vitreomacular traction, including when associated with macular hole ≤ 400 μm: A Swedish perspective. Gairy K. Bennison C. Thurston S. Lescrauwaet B. Aaberg J. Acta Ophthalmologica (2014) 92 SUPPL. 254 (21). Date of Publication: December 2014

      • Visual function and anatomic responses to ocriplasmin. Jackson T. Verstraeten T. Duchateau L. Lescrauwaet B. Value in Health (2014) 17:3 (A283). Date of Publication: May 2014

      • Management of vitreomacular traction (VMT) by vitrectomy in France: A retrospective hospital database analysis (PMSI). Bénard S. Schmidt A. Zech J.C. Korobelnik J.F. Guignard E. Moro L. Lescrauwaet B. Value in Health (2014) 17:3 (A284). Date of Publication: May 2014

      • Ocriplasmin for the treatment of vitreomacular traction and macular holes: Long-term modelling of clinical and economic value of resolution of traction in France. Moro L. Bennison C. Thurston S. Lescrauwaet B. Value in Health (2014) 17:3 (A287). Date of Publication: May 2014

      • Visual function response to ocriplasmin for the treatment of vitreomacular traction and macular hole. Jackson T. Verstraeten T. Duchateau L. Lescrauwaet B. Value in Health (2014) 17:3 (A289). Date of Publication: May 2014

      • Baseline characteristics and vitreoretinal interface features in patients with vitreomacular traction and macular hole from the MIVI-TRUST clinical program. Lescrauwaet B. Koshy Z. Labourette A. Duchateau L. Value in Health (2013) 16:7 (A502). Date of Publication: November 2013

      • Baseline patient, ocular features and management of a patient population diagnosed with vitreomacular traction: An observational study in Flanders. Lescrauwaet B. Spaepen E. Vriens I. Stalmans P. Value in Health (2013) 16:7 (A502). Date of Publication: November 2013

      • Utility estimation for visual acuity health states: An original and pragmatic approach to transpose published evidence into a more flexible estimation. Bennison C. Thurston S. Lescrauwaet B. Bojakowski S. Kozma-Wiebe P. Value in Health (2012) 15:7 (A468). Date of Publication: November 2012
    • Viral hepatitis
      • The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: A systematic review and network meta-analysis. Mealing S. Ghement I. Hawkins N. Scott D.A. Lescrauwaet B. Watt M. Thursz M. Lampertico P. Mantovani L. Morais E. Bregman B. Cucherat M. Systematic Reviews (2014) 3:1 Article Number: 21. Date of Publication: 7 Mar 2014

      • Multicountry burden of chronic hepatitis C viral infection among those aware of their diagnosis: A patient survey. DiBonaventura M.D. Yuan Y. Lescrauwaet B. L'Italien G. Liu G.G. Kamae I. Mauskopf J.A. PLoS ONE (2014) 9:1 Article Number: e86070. Date of Publication: 21 Jan 2014

      • Predictors associated with treatment initiation and switch in a real-world chronic hepatitis B population from five European countries. Leblebicioglu H. Arama V. Causse X. Marcellin P. Ozaras R. Postawa-Klozinska B. Simon K. Suceveanu A.I. Wiese M. Zeuzem S. Klauck I. Morais E. Bjork S. Lescrauwaet B. Kamar D. Zarski J.P. Journal of Viral Hepatitis (2014) 21:9 (662-670). Date of Publication: September 2014

      • Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies. Arama V. Leblebicioglu H. Simon K. Zarski J.P. Niederau C. Habersetzer F. Vermehren J. Bludzin W. Jinga M. Ulusoy S. Klauck I. Morais E. Bjork S. Lescrauwaet B. Kamar D. Zeuzem S. Marcellin P. Botta-Fridlund D. Pol S. Maynard M. Causse X. Alric L. Noumbissie P.S. Mauss S. Gerken G. Goeser T. Wiese M. Busch H. Schneider L. Schubert J. Brenner M. Scheffrahn I. Dziambor A. Goryszewski D. Postawa-Klosinska B. Sieklucki J. Pleśniak R. Acalovschi M. Tanasescu C. Raducan L. Sporea I. Voiculescu M. Chira O. Arama S.S. Radulescu M.A. Nicolau A. Nitescu D. Munteanu D.I. Nanu A. Dan I. Nicolita D. Ionescu C. Ecobici M. Micu G. Parepa R.I. Suceveanu A. Usluer G. Baskol M. Ozaras R. Esen S. Kartal E.D. Antiviral Therapy (2014) 19:3 (245-257). Date of Publication: 2014

      • Chronic hepatitis B treatment initiation and modification patterns in five European countries: A 2-year longitudinal, non-interventional study. Marcellin P. Arama V. Leblebicioglu H. Zarski J.P. Zeuzem S. Mauss S. Sieklucki J. Acalovschi M. Usluer G. Klauck I. Morais E. Bjork S. Lescrauwaet B. Kamar D. Simon K. Botta-Fridlund D. Pol S. Maynard M. Habersetzer F. Causse X. Alric L. Noumbissie P.S. Gerken G. Goeser T. Niederau C. Wiese M. Busch H. Schneider L. Schubert J. Brenner M. Scheffrahn I. Vermehren J. Bludzin W. Dziambor A. Goryszewski D. Postawa-Klosinska B. Pleśniak R. Tanasescu C. Raducan L. Sporea I. Jinga M. Voiculescu M. Chira O. Arama S.S. Radulescu M.A. Nicolau A. Nitescu D. Nanu A. Dan I. Nicolita D. Ionescu C. Ecobici M. Micu G. Parepa R.I. Suceveanu A. Baskol M. Ozaras R. Ulusoy S. Esen S. Kartal E.D. Yamazhan T. Antiviral Therapy (2014) 19:3 (235-243). Date of Publication: 2014

      • Do you need to account for baseline viral load when assessing the relative efficacy of interventions for treatment naïve HBeag positive chronic hepatitis B (CHB) patients? Results from unadjusted and adjusted network meta-analyses (NMA). Mealing S. Ghement I. Ali S. Hawkins N. Scott D.A. Lescrauwaet B. Thursz M. Lampertico P. Mantovani L. Morais E. Bjork S. Bregman B. Cucherat M. Value in Health (2013) 16:3 (A211-A212). Date of Publication: May 2013

      • The use of individual patient-level data (IPD) to quantify the impact of pretreatment predictors of response to treatment in chronic hepatitis B patients. Ali S. Mealing S. Hawkins N. Lescrauwaet B. Bjork S. Mantovani L. Lampertico P. BMJ Open (2013) 3:1 Article Number: A37. Date of Publication: 2013

      • Non-interventional study AI463-12 of real-world chronic HBV infection management--baseline characteristics and treatment patterns of Polish patients kohort. Simon K. Błudzin W. Dziambor A. Goryszewski D. Postawa-Kłosińska B. Sieklucki J. Kolasa K. Lescrauwaet B. Przegla̧d epidemiologiczny (2013) 67:4 (617-621, 709-712). Date of Publication: 2013

      • Multivariate cox analysis regarding treatment switch on chronic hepatitis B (CHB) disease management based on a 2-year prospective study in 5 european (EU) countries. Arama V. Zeuzem S. Leblebicioglu H. Simon K. Klauck I. Morais E. Lescrauwaet B. Kamar D. Zarski J. Value in Health (2012) 15:7 (A399-A400). Date of Publication: November 2012

      • Combining an ordered logit model with individual patient-level data to robustly estimate within-category visual acuity starting distributions: An innovative modeling approach in the case of vitreomacular traction. Bennison C. Thurston S. Lescrauwaet B. Bojakowski S. Kozma-Wiebe P. Value in Health (2012) 15:7 (A486). Date of Publication: November 2012

      • A 2-year analysis of chronic hepatitis B management in five European countries: Treatment initiation factors and the impact of healthcare policies. Simon K. Arama V. Zarski J. Zeuzem S. Lescrauwaet B. Kamar D. Klauck I. Morais E. Leblebicioglu H. Journal of Viral Hepatitis (2012) 19 SUPPL. 3 (1-2). Date of Publication: September 2012

      • Multivariate Cox analysis on chronic hepatitis B treatment initiation based on a 2-year prospective study in five European countries. Leblebicioglu H. Zeuzem S. Zarski J. Simon K. Klauck I. Morais E. Lescrauwaet B. Kamar D. Arama V. Journal of Viral Hepatitis (2012) 19 SUPPL. 3 (23-24). Date of Publication: September 2012

      • Impact of healthcare policies on the clinical management of chronic hepatitis B: Analysis of real-world data from five European countries. Simon K. Arama V. Zarski J. Zeuzem S. Lescrauwaet B. Kamar D. Klauck I. Morais E. Leblebicioglu H. Journal of Viral Hepatitis (2012) 19 SUPPL. 3 (24). Date of Publication: September 2012

      • The burden of viral hepatitis C in Europe: A propensity analysis of patient outcomes. DaCosta DiBonaventura M. Yuan Y. Wagner J.-S. L'Italien G.J. Lescrauwaet B. Langley P. European Journal of Gastroenterology and Hepatology (2012) 24:8 (869-877). Date of Publication: August 2012

      • The humanistic and economic burden of Hepatitis C across the United States, Europe, and Asia. DiBonaventura M.D. Yuan Y. Lescrauwaet B. L'Italien G. Liu G.G. Kamae I. Mauskopf J.A. Value in Health (2012) 15:4 (A245-A246). Date of Publication: June 2012

      • Physicians' stated trade-off preferences for chronic hepatitis B treatment. outcomes in Germany, France, Spain, Turkey, and Italy. Mohamed A.F. Reed Johnson F. Brett Hauber A. Lescrauwaet B. Masterson A. European Journal of Gastroenterology and Hepatology (2012) 24:4 (419-426). Date of Publication: April 2012

      • Real-world data on treatment modification from a long-term observational study of chronic Hepatitis B patients from 5 European countries. Zarski J.P. Amara V. Leblebicioglu H. Zeuzem S. Lescrauwaet B. Kamar D. Klauck I. Morais E. Simon K. Journal of Hepatology (2012) 56 SUPPL. 2 (S194). Date of Publication: April 2012

      • The effect of Hepatitis C treatment on health-related quality of life, work productivity, and healthcare resource use among patients in Europe. Di Bonaventura M. Yuan Y. L'Italien G. Lescrauwaet B. Journal of Hepatology (2012) 56 SUPPL. 2 (S434). Date of Publication: April 2012

      • Real word data on patient characteristics and disease management patterns of chronic hepatitis B in five European countries. Zeuzem S. Arama V. Kamar D. Klauck I. Leblebicioglu H. Lescrauwaet B. Morais E. Simon K. Zarski J.P. Hepatology International (2012) 6:1 (100). Date of Publication: January 2012

      • Clinical outcomes analysis comparing entecavir with lamivudine monotherapy and lamivudine with “tenofovir add-on as needed” approach in the treatment of chronic hepatitis B infection in Turkey. Ozdemir O. Saylan M. Yegnidemir N. Lescrauwaet B. Value in Health (2011) 14:7 (A266). Date of Publication: November 2011

      • A decision tree model comparing clinical outcomes of treatment with telbivudine with or without “tenofovir add-on as needed” and lamivudine with or without “tenofovir add-on as needed” in the treatment of chronic hepatitis B infection in Turkey. Ozdemir O. Saylan M. Pakel H. Lescrauwaet B. Value in Health (2011) 14:7 (A266-A267). Date of Publication: November 2011

      • Current treatments for chronic hepatitis B: A systematic review. Watt M. Mealing S. Huerta M. Eaton V. Lescrauwaet B. Mesa O.A. Thursz M. Hawkins N. Value in Health (2011) 14:7 (A392). Date of Publication: November 2011

      • Do patients and physicians have similar preferences chronic hepatitis N treatment outcomes in Turkey? Mohamed A. Johnson F.R. Hauber A.B. Lescrauwaet B. Saylan M. Value in Health (2011) 14:7 (A282). Date of Publication: November 2011

      • Real world data on long term treatment initiation in patients with chronic hepatitis B: Cohort observations in France, Germany, Poland, Romania and Turkey. Lescrauwaet B. Arama V. Leblebicioglu H. Simon K. Zarski J.-P.H. Zeuzem S. Hepatology (2011) 54 SUPPL. 1 (586A-587A). Date of Publication: October 2011

      • Do patients and physicians have similar preferences for healthcare decisions involving uncertain outcomes for chronic hepatitis B in Germany and Turkey? Lescrauwaet B. Mohamed A.F. Johnson F.R. Hauber A.B. Value in Health (2011) 14:3 (A121). Date of Publication: May 2011

      • Modeling the long term consequences of suppressing viral replication in chronic hepatitis B: A cost-effectiveness analysis of entecavir (baraclude®) in Turkey. Lescrauwaet B. Saylan M. Malhan S. Öksüz E. Korkmaz M. Kursun E. Eminsoy G. Value in Health (2010) 13:7 (A370). Date of Publication: November 2010

      • Patient preferences for benefits, risks, and weight of evidence associated with hepatitis b treatments. Mohamed A. Johnson F.R. Hauber A.B. Lescrauwaet B. Masterson A. Value in Health (2010) 13:7 (A441). Date of Publication: November 2010

      • Is it possible to obtain willingness-to-pay estimates in Europe? A validity test of stated preferences for hepatitis-b treatments. Johnson F.R. Mohamed A. Hauber A.B. Lescrauwaet B. Value in Health (2010) 13:7 (A445). Date of Publication: November 2010

      • A cross-sectional analysis of chronic hepatitis B patient characteristics and clinical management patterns in Germany, Poland, Romania and Turkey. Lescrauwaet B. Gwed S. Ponsonnet D. Arama V. Leblebicioglu H. Simon K. Zarski J.-P. Zeuzem S. Journal of Hepatology (2010) 52 SUPPL. 1 (S279-S280). Date of Publication: April 2010
    • HIV
      • Cost-effectiveness of treatment initiation with ritonavirboosted atazanavir (ATV/R) and lopinavir (LPV/R) in treatment naïve HIV patients at different CD4 levels at baseline. Verheggen B. Aldir I. Tan C. Carrasco J. Antunes A. Lescrauwaet B. Value in Health (2012) 15:4 (A243-S244). Date of Publication: June 2012

      • Comparing the efficacy and tolerability of anti-retroviral therapy in treatment-naïve HIV-1 infected adults: A systematic review of randomized clinical trials and bayesian mixed treatment comparisons including Atazanavir/R, Darunavir/R, Lopinavir/R, and Efavirenz. Verheggen B. Vandeloise E. Treur M. Thuresson P.O. Lescrauwaet B. Value in Health (2011) 14:7 (A265-A266). Date of Publication: November 2011

      • Modeling the long term clinical outcomes and health care cost impact of initiating treatment with atazanavir/r compared with darunavir/r, lopinavir/r and efavirenz for hiv-1 infected treatment-naïve patients: Country results for Italy, Spain, Portugal and UK. Thuresson P.O. Verheggen B. Heeg B. Aldir I. Carrasco J. Didoni G. Mesa O.A. Lescrauwaet B. Value in Health (2011) 14:7 (A278-A279). Date of Publication: November 2011

      • Cost-effectiveness of atazanavir/r compared to darunavir/r in Germany. Thuresson P.O. Verheggen B. Heeg B. Kaspar I. Erhardt W. Lescrauwaet B. Value in Health (2011) 14:7 (A280). Date of Publication: November 2011

      • Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden. Thuresson P.-O. Heeg B. Lescrauwaet B. Sennfält K. Alaeus A. Neubauer A. Scandinavian Journal of Infectious Diseases (2011) 43:4 (304-312). Date of Publication: April 2011

      • Patient classification and cost analysis of aids and HIV: The case of Belgium. De Graeve D. Lescrauwaet B. Nonneman W. Health Policy (1997) 39:2 (93-106). Date of Publication: February 1997
    • Cognitive impairment
      • Detection of cognitive impairment and dementia using the animal fluency test: The DECIDE Study. Sebaldt R. Dalziel W. Massoud F. Tanguay A. Ward R. Thabane L. Melnyk P. Landry P.-A. Lescrauwaet B. Canadian Journal of Neurological Sciences (2009) 36:5 (599-604). Date of Publication: 1 Sep 2009
    • COPD
      • Drug utilization review of cholinesterase inhibitors in Quebec. Massoud F. Dorais M. Charbonneau C. Lescrauwaet B. Boucher J.-M. LeLorier J. Canadian Journal of Neurological Sciences (2008) 35:4 (508-509). Date of Publication: September 2008
    • Diabetes
      • Risking health to avoid injections: Preferences of Canadians with type 2 diabetes. Hauber A.B. Johnson F.R. Sauriol L. Lescrauwaet B. Diabetes Care (2005) 28:9 (2243-2245). Date of Publication: September 2005
    Open all
Open all